Interleukin-10 at the crossroads of immunity in TLR7-induced lupus

• by Johanna Pauline Williams, Anaïs Amend, Anna-Lena Schäfer, Paola Fernanda Ruiz-Aparicio, Antoine Nicolas Kraemer, Aileen Qian Luo, Laura Riechert, Lara Weber, Baerbel Keller, Rudolf Armin Manz, Reinhard Edmund Voll, Nina Chevalier

• June 22, 2026

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

• by Kathryn Wighton

• June 5, 2026

• 4 min

Correction: Baseline neutrophil-to-lymphocyte ratio combined with SLEDAI predicts lupus low disease activity state at 1 year: a cohort study

• by Yadan Zou, Ruohan Yu, Kun Yang, Lina Zhang, Jing Zhang, Ji Li, Ting Long, Yanfeng Zhang, Sheng-Guang Li

• July 6, 2026

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

• by Kathryn Wighton

• July 7, 2026

• 3 min